secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004131
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics reports pipeline progress, ~$1B cash, and outlines milestones for 2023-2024
--------------------------------------------------------------------------------

- Estimated $1.0B cash, cash equivalents, and marketable securities as of Dec 31, 2022; cash runway expected into 2025.
- BEAM-101 (SCD): BEACON trial sentinel cohort enrollment completion and expansion cohort initiation expected in 2023; data from multiple patients in 2024.
- BEAM-201 (T-ALL/T-LL): FDA IND clearance; first patient dosing expected by mid-2023 in Phase 1/2 trial.
- BEAM-301 (GSDIa) regulatory submission planned by late 2023/early 2024; BEAM-302 (AATD) submission planned early 2024.
- North Carolina manufacturing facility expected to initiate GMP operations in late 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000119312523004131/0001193125-23-004131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000119312523004131/d393225d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer